Healio4d
Trial supports sotatercept as standard of care for high-risk patients with PAH
Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...
BioSpace3d
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
MPR1d
Sotatercept Reduces Major Events in High-Risk PAH Patients
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
2 Minute Medicine10d
Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule
Strong positive interim data from an earlier Phase 3 trial has led to early cessation of Merck’s pulmonary arterial ...